Flexion Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, such as osteoarthritis (OA), a type of degenerative arthritis. The Company's portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company's products include FX006, which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007, which is indicated for post-operative pain, and FX005, which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.